charged multivesicular body protein 4BGenealiases: C20orf178 · CHMP4A · CTPP3 · CTRCT31 · SNF7 · SNF7-2
Q-omics provides the consensus-scored CHMP4B profile across patient tissues and cancer cell-line models. CHMP4B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHMP4B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CHMP4B RNA expression shows 19,434 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where CHMP4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHMP4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHMP4B survival associations across molecular data types. CHMP4B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHMP4B RNA expression–survival associations across cancer types. High CHMP4B expression shows unfavorable associations in UVM, LIHC, PAAD, LAML, KICH and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for CHMP4B RNA expression.
This table summarizes CHMP4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHMP4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHMP4B shows higher tumor expression in HNSC, KIRC, LIHC, LUAD, KIRP and BRCA. The HNSC box plot shows higher CHMP4B RNA expression in tumor versus normal tissue (log2 FC = +0.707, t-test p < 0.001).
This table shows molecular features associated with CHMP4B in patient tissues and cancer cell lines. In patient samples, CHMP4B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHMP4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
